Lexston Life Sciences Corp. (LEXTF)
USD 0.13
(83.92%)
USD 0.13
(83.92%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 | 39.86 Thousand CAD | 255.75% |
| 2023 | 11.2 Thousand CAD | -85.83% |
| 2022 | 79.08 Thousand CAD | 103.79% |
| 2021 | 38.8 Thousand CAD | 1880.0% |
| 2020 | 1960.00 USD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 22.16 Thousand CAD | 2.58% |
| 2024 Q4 | 39.86 Thousand CAD | 33.16% |
| 2024 Q3 | 29.94 Thousand CAD | 35.08% |
| 2024 Q1 | 21.6 Thousand CAD | 92.79% |
| 2023 Q2 | 8596.00 CAD | -82.25% |
| 2023 Q1 | 48.41 Thousand CAD | -38.78% |
| 2023 Q4 | 11.2 Thousand CAD | 25.68% |
| 2023 FY | 11.2 Thousand CAD | -85.83% |
| 2023 Q3 | 8917.00 CAD | 3.73% |
| 2022 FY | 79.08 Thousand CAD | 103.79% |
| 2022 Q3 | 81 Thousand CAD | -21.04% |
| 2022 Q2 | 102.59 Thousand CAD | -17.82% |
| 2022 Q1 | 124.83 Thousand CAD | 0.0% |
| 2022 Q4 | 79.08 Thousand CAD | -2.37% |
| 2021 Q2 | 3858.32 USD | 0.0% |
| 2021 FY | 38.8 Thousand CAD | 1880.0% |
| 2020 FY | 1960.00 USD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Evofem Biosciences, Inc. | 72.47 Million USD | 99.945% |
| Arch Therapeutics, Inc. | 9.46 Million USD | 99.579% |
| CSL Limited | 18.62 Billion USD | 100.0% |
| Santhera Pharmaceuticals Holding AG | 59.01 Million USD | 99.932% |
| Regen BioPharma, Inc. | 5.45 Million USD | 99.269% |
| BioStem Technologies, Inc. | 15.9 Million USD | 99.749% |
| Capstone Therapeutics Corp. | 50.26 Million USD | 99.921% |
| Qrons Inc. | 1.48 Million USD | 97.322% |
| Nascent Biotech, Inc. | 808.79 Thousand USD | 95.071% |
| Northwest Biotherapeutics, Inc. | 74.92 Million USD | 99.947% |
| Oncotelic Therapeutics, Inc. | 18.4 Million USD | 99.783% |
| Skye Bioscience, Inc. | 14.07 Million USD | 99.717% |
| ProtoKinetix, Incorporated | 44.69 Thousand USD | 10.8% |
| Rebus Holdings, Inc. | 5.24 Million USD | 99.239% |
| Acro Biomedical Co., Ltd. | 201.11 Thousand USD | 80.176% |
| Burzynski Research Institute, Inc. | 27.43 Thousand USD | -45.332% |
| Genscript Biotech Corporation | 1.32 Billion USD | 99.997% |
| Neon Bloom, Inc. | 1.22 Million USD | 96.749% |
| Adynxx, Inc. | - USD | -Infinity% |
| Eiger BioPharmaceuticals, Inc. | 53.3 Million USD | 99.925% |
| Nanobac Pharmaceuticals, Incorporated | 9.58 Million USD | 99.584% |
| Institute of Biomedical Research Corp. | 421.56 Thousand USD | 90.543% |
| SQZ Biotechnologies Company | 50.03 Million USD | 99.92% |
| Intellipharmaceutics International Inc. | 12 Million USD | 99.668% |
| Propanc Biopharma, Inc. | 3.85 Million USD | 98.965% |
| Mesoblast Limited | 188.44 Million USD | 99.979% |
| Marizyme, Inc. | 26.67 Million USD | 99.851% |
| Genus plc | 485 Million USD | 99.992% |
| VioQuest Pharmaceuticals, Inc. | 5.84 Million USD | 99.318% |
| Pharming Group N.V. | 244.07 Million USD | 99.984% |
| Therapeutic Solutions International, Inc. | 2.01 Million USD | 98.017% |
| CNBX Pharmaceuticals Inc. | 2.51 Million USD | 98.416% |
| Nymox Pharmaceutical Corporation | 3.8 Million USD | 98.951% |
| ContraFect Corporation | 32.53 Million USD | 99.877% |
| PsyBio Therapeutics Corp. | 1.98 Million USD | 97.988% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 3.82 Million USD | 98.958% |
| IMV Inc. | 37.93 Million USD | 99.895% |
| AXIM Biotechnologies, Inc. | 11.77 Million USD | 99.662% |
| MultiCell Technologies, Inc. | 1617.67 USD | -2364.594% |
| ONE Bio Corp. | 27.49 Million USD | 99.855% |
| Accustem Sciences Inc. | 1.07 Million USD | 96.306% |
| RVL Pharmaceuticals plc | 77.41 Million USD | 99.949% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 2.11 Million USD | 98.115% |
| Q BioMed Inc. | 8.13 Million USD | 99.51% |
| Emmaus Life Sciences, Inc. | 82.93 Million USD | 99.952% |
| Mosaic ImmunoEngineering Inc. | 5.14 Million USD | 99.225% |
| Biomind Labs Inc. | 1.49 Million USD | 97.34% |
| American Oriental Bioengineering, Inc. | 118.72 Million USD | 99.966% |
| Provectus Biopharmaceuticals, Inc. | 9.04 Million USD | 99.559% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| GlobeStar Therapeutics Corporation | 1.43 Million USD | 97.219% |
| THC Farmaceuticals, Inc. | 142.09 Thousand USD | 71.942% |
| Curative Biotechnology, Inc. | 5.74 Million USD | 99.306% |
| GB Sciences, Inc. | 5.41 Million USD | 99.264% |
| Alpha Cognition Inc. | 7.16 Million USD | 99.444% |
| HST Global, Inc. | 593.59 Thousand USD | 93.283% |
| Wesana Health Holdings Inc. | 1.25 Million USD | 96.834% |
| Halberd Corporation | 728.71 Thousand USD | 94.529% |
| Enzolytics Inc. | 365.26 Million USD | 99.989% |
| Agentix Corp. | 2.51 Million USD | 98.412% |
| Resverlogix Corp. | 67.39 Million USD | 99.941% |
| Nuo Therapeutics, Inc. | 838.73 Thousand USD | 95.247% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 444.95 Million USD | 99.991% |
| Enzon Pharmaceuticals, Inc. | 1.71 Million USD | 97.674% |
| Endonovo Therapeutics, Inc. | 24.74 Million USD | 99.839% |
| RespireRx Pharmaceuticals Inc. | 11.9 Million USD | 99.665% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 3.66 Million USD | 98.912% |
| AVAX Technologies, Inc. | 3.99 Million USD | 99.002% |
| Zenith Capital Corp. | 27.56 Thousand USD | -44.615% |
| Ember Therapeutics, Inc. | 238.65 Thousand USD | 83.294% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 3.73 Million USD | 98.932% |
| WPD Pharmaceuticals Inc. | 680.83 Thousand USD | 94.144% |
| Cotinga Pharmaceuticals Inc. | 2.71 Million USD | 98.53% |
| Kadimastem Ltd | 3.5 Million USD | 98.862% |
| Helix BioMedix, Inc. | 66.92 Thousand USD | 40.431% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 464.69 Thousand USD | 91.42% |
| LadRx Corporation | 2.2 Million USD | 98.188% |
| Cell Source, Inc. | 15.8 Million USD | 99.748% |
| Regen BioPharma, Inc. | 5.45 Million USD | 99.269% |
| NovAccess Global Inc. | 7.86 Million USD | 99.493% |
| Affymax, Inc. | 8.87 Million USD | 99.551% |
| Itoco Inc. | 1.65 Million USD | 97.588% |
| Rasna Therapeutics, Inc. | 2.05 Million USD | 98.057% |
| Pathfinder Cell Therapy, Inc. | 6.04 Million USD | 99.341% |
| Mobile Lads Corp. | 1.31 Million USD | 96.965% |
| CytoDyn Inc. | 127.89 Million USD | 99.969% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 41.79 Thousand USD | 4.617% |
| NanoSphere Health Sciences Inc. | 1.56 Million USD | 97.455% |
| Alseres Pharmaceuticals, Inc. | 11.04 Million USD | 99.639% |
| SYBLEU INC | 681.41 Thousand USD | 94.149% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 6.1 Million USD | 99.347% |
| International Stem Cell Corporation | 5.27 Million USD | 99.244% |
| Bioxytran, Inc. | 3.24 Million USD | 98.773% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 625.8 Thousand USD | 93.629% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 4.61 Million USD | 99.136% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 40.99 Million USD | 99.903% |
| Adhera Therapeutics, Inc. | 22.26 Million USD | 99.821% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 2.02 Million USD | 98.032% |
| Innovation Pharmaceuticals Inc. | 5.47 Million USD | 99.272% |
| Neutra Corp. | 973.52 Thousand USD | 95.905% |
| Windtree Therapeutics, Inc. | 29.01 Million USD | 99.863% |
| PureTech Health plc | 125.58 Million USD | 99.968% |
| Coeptis Therapeutics, Inc. | 3.75 Million USD | 98.939% |
| IXICO plc | 1.9 Million USD | 97.902% |
| IntelGenx Technologies Corp. | 20.52 Million USD | 99.806% |
| Gelesis Holdings, Inc. | 103.32 Million USD | 99.961% |
| CSL Limited | 18.62 Billion USD | 100.0% |
| Cellectis S.A. | 249.36 Million USD | 99.984% |